Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prostate Cancer Market Snapshot: More Than Provenge

Executive Summary

The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.
Advertisement

Related Content

Exelixis Explains Cabozantinib Thyroid Cancer Delay As Prostate Program Takes Shape
Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
Provenge Coverage With Data Collection Suggested By MEDCAC Members
Provenge Coverage With Data Collection Suggested By MEDCAC Members
Is Provenge "Reasonable And Necessary"? CMS Analysis For Medicare Coverage Seeks To Find Out
With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use
With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use
Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price

Topics

Advertisement
UsernamePublicRestriction

Register

PS052859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel